APTV vs BALL

The deterministic health scores present a mixed picture: the Piotroski F-Score of 4/9 indicates stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a high current P/E of 58.82, the forward P/E of 9.01 suggests strong earnings growth expectations. The company beats earnings estimates consistently, with a 3/4 beat rate over the last four quarters and an average surprise of 14.89%, yet insider selling and weak long-term price performance raise caution. While analysts are bullish with a $101.81 target price and a 'buy' recommendation, the stock trades at a significant premium to the Graham Number of $35.41, implying high valuation risk.

The Advanced Deterministic Scorecard reveals significant concerns, most notably a weak Piotroski F-Score of 3/9, indicating poor financial health based on fundamental criteria. Despite strong recent earnings growth (YoY +81.1%) and a reasonable forward P/E of 14.44, the company faces liquidity constraints (Quick Ratio: 0.68) and high leverage (Debt/Equity: 1.38). Analysts recommend a 'buy' with a $62.69 target, implying upside, but insider selling and inconsistent earnings beats (0/4 recent quarters) temper optimism. The stock trades above the Graham Number ($34.5) but below intrinsic value ($77.29), suggesting mixed valuation signals.